Opening question: When a research-peptide listing flashes a Sulfinator “tyrosine sulfation” hit table, how do you separate secretory-pathway PTM prediction from proof the product is cleared for people?
Short answer: open the live ExPASy Sulfinator tool and its documentation plus the reference the site lists, Monigatti et al., Bioinformatics (2002) (PubMed 12050077 on the reference page). Sulfinator predicts tyrosine sulfation sites in protein sequences using hidden Markov models trained for different sequence contexts. That is tyrosine-sulfation PTM literacy for proteins that go through the secretory pathway. It is not a medicines review of a catalog SKU.
A practical Sulfinator checklist when listings lean on sulfation screenshots:
- What the tool predicts: ExPASy’s page and docs describe prediction of potentially sulfated tyrosines, with output positions and related sequence context. A predicted site is an in silico PTM call—not clinical clearance.
- Sulfation ≠ phosphorylation tools: Phospho-site predictors such as NetPhos answer a different modification. If an ad pastes “PTM validated” while mixing Sulfinator and phospho screenshots, ask which modification and which named server were used.
- Secretory-pathway context matters: The tool page notes tyrosine sulfation as important for proteins that go through the secretory pathway. Cropped tables without that biological frame oversell a motif score as product proof.
- Mass-difference PTM matchers are different: Tools such as FindMod interpret peptide-mass differences. Sulfinator is sequence-based sulfation-site prediction—not the same evidence class.
- What to open next: If a listing implies a research peptide is “Sulfinator-validated,” open the live Sulfinator page, documentation, and Monigatti et al. reference and ask whether the claim teaches tyrosine-sulfation literacy—or implies human-use meaning from a PTM table.
None of those steps turns a laboratory research listing into an approved medicine. Company research-only catalogs document laboratory intent and paperwork such as certificates of analysis; they do not create human-use approval. For company facts only—not clinical evidence—Apollo Peptides states products are for laboratory research only, not for human or veterinary use, and describes third-party testing with certificates of analysis.
Bottom line: Use Sulfinator to understand predicted tyrosine sulfation sites, then notice whether the listing is teaching secretory-pathway PTM literacy—or dressing a research chemical with modification jargon. That habit changes what you verify before trusting a sulfation badge—it is not advice to buy, inject, or dose any peptide.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against the ExPASy Sulfinator tool page, documentation, and reference page listing Monigatti et al. Bioinformatics 2002 (fetched 2026-10-02 PT). No invented studies, quotes, or dosing. Not medical or legal advice.
Sources
1. ExPASy Sulfinator — tyrosine sulfation prediction
2. Sulfinator documentation (ExPASy)
3. Sulfinator reference — Monigatti et al. Bioinformatics 2002
4. Apollo Peptides (company facts only)
Related reading
NetPhos phosphorylation scores are not catalog clearance
FindMod PTM mass-difference tables are not human-use approval
NetAcet N-terminal acetylation scores are not research-peptide clearance